William Blair downgraded Poseida Therapeutics (PSTX) to Market Perform from Outperform after Roche (RHHBY) agreed to acquire Poseida for $13 per share in cash, comprised of $9 per share in cash at closing and a non-tradeable contingent value right to receive up to $4 per share in cash upon achievement of specific milestones.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PSTX:
- Poseida Therapeutics downgraded to Neutral from Buy at BTIG
- Poseida Therapeutics downgraded to Neutral from Overweight at Cantor Fitzgerald
- Poseida Therapeutics to be acquired by Roche for $9.00 per share plus CVR
- Poseida Therapeutics Advances in Cell Therapy Innovations
- Poseida Therapeutics holds virtual R&D Day